


JAN. 28, 2023

Course Directors:

Fernando A. Angarita, MD, MSc, FRCSC, and Candy Arentz, MD, MBA, FACS







Breast Cancer Updates for Primary Care Saturday, January 28, 2023 Houston Methodist Research Institute

AGENDA

TIME	PRESENTATION	SPEAKER(S)
8:00 - 8:10 AM	Welcome and Introductions	
8:15 - 8:35 AM	Benign Breast Disease	Sandra F. Templeton, MD, FACS
8:40 - 9:00 AM	Breast Cancer Screening Methods and Recommendations	Rajul R. Mehta, MD
9:05 - 9:25 AM	Breast Cancer Risk and Genetics	Tiffiney G. Carter, MS, CGC
9:30 - 9:45 AM	Multidisciplinary Approach to Breast Cancer Treatment	Candy Arentz, MD, FACS
9:45 - 10:00 AM	Break and Exhibits	
10:00 - 10:20 AM	Surgery of the Breast and Axilla	Fernando A. Angarita, MD, MSc, FRCSC
10:20 - 10:40 AM	Role of Radiation Therapy	Bin S. Teh, MD, FACR, FASTRO, FACRO
10:45 - 11:05 AM	Breast Reconstruction	Jeffrey D. Friedman, MD
11:05 - 11:30 AM	Role of Systemic Therapy	Polly A. Niravath, MD
11:30 - 12:00 PM	Breast Cancer Survivorship	Shayo Omidele, MSN, APRN, NP-C with Special Guest: Dawn Compton, Breast Cancer Survivor
12:00 - 12:30 PM	Question and Answer and Closing Remarks	
12:30 PM	Adjourn	

Click the link of the presentation to view the slides (PDF)*.

Slides are posted as they become available. Some slides may not be posted.

Refresh this link to check for updates.

Links not showing? We suggest trying another browser or downloading this pdf and open with a pdf viewer.



Breast Cancer Updates for Primary Care Saturday, January 28, 2023 Houston Methodist Research Institute

FACULTY

COURSE DIRECTORS

Fernando A. Angarita, MD, MSc, FRCSC

Division of Surgical Oncology and Gastrointestinal Surgery, Department of Surgery

Houston Methodist Hospital

Assistant Professor of Surgery

Houston Methodist

Weill Cornell Medical College

Candy Arentz, MD, MBA, FACS

Medical Director, Breast Program

Department of Surgery, Houston Methodist West

Associate Professor of Clinical Surgery

Houston Methodist Department of Surgery

SPECIAL GUEST

Dawn Compton

Founder, Blessing Box Project

Breast Cancer Survivor

HOUSTON METHODIST FACULTY

Tiffiney G. Carter, MS, CGC

Certified Genetic Counselor, Oncology Administration Services

Houston Methodist Sugar Land Hospital

Jeffrey D. Friedman, MD

Cathy and Ed Frank Centennial Chair in Plastic and Reconstructive Surgery, Department of Surgery

Associate Professor of Plastic Surgery

Division Chief, Reconstructive Surgery, Department of Surgery

Houston Methodist

Weill Cornell Medical College

Rajul R. Mehta, MD

Instructor in Radiology, Academic Institute

Houston Methodist

Weill Cornell Medical College

Polly A. Niravath, MD

Section Chief, Breast Oncology

Director, Cancer Survivorship Program

Lois E. and Carl A. Davis Centennial Associate Professor in Cancer Research, Dr. Mary and Ron Neal Cancer Center

Associate Professor of Medicine

Houston Methodist

Weill Cornell Medical College

Shayo Omidele, MSN, APRN, NP-C

Oncology Nurse Practitioner

Houston Methodist

Bin S. Teh, MD, FACR, FASTRO, FACRO

Professor of Radiation Oncology

Jim and Joan Harrell Centennial Chair in Radiation Oncology

Houston Methodist

Weill Cornell Medical College

Sandra Templeton, MD, FACS

Assistant Professor of Surgery

Houston Methodist Department of Surgery

Houston Methodist

Weill Cornell Medical College



Breast Cancer Updates for Primary Care Saturday, January 28, 2023 Houston Methodist Research Institute

PROGRAM OVERVIEW

Breast cancer is the most common cancer and the second leading cause of cancer deaths among women in the United States. The goal of this conference is to provide primary care providers from various backgrounds with important updates about breast cancer that can be incorporated into their practice. The conference aims to help bridge the rapidly widening gap between primary care and the latest knowledge about breast cancer risk factors, current screening methods and guidelines, state-of-the-art multimodal treatment, and issues related to survivorship and quality of life.

TARGET AUDIENCE

Primary care physicians, internists, family medicine practitioners, hospitalists, physician assistants, nurse practitioners, nurses, residents, fellows, and medical students will benefit from this course.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, the participant should be able to:

- Discuss benign breast disease with increased risk for breast cancer
- Discuss risk factors for breast cancer and current screening methods and guidelines
- Discuss the implications of genetic syndromes and mutations on breast cancer risk, screening and treatment recommendations, and survivorship
- Recognize the advantages of breast cancer care in a multidisciplinary setting
- Discuss surgical options for breast cancer
- Discuss reconstruction options for breast cancer
- Discuss the role of systemic and radiation therapy in curative and palliative settings
- Recognize the impact of surgery, systemic therapy, and radiation therapy on quality of life and survivorship

NURSING OUTCOMES STATEMENT

Upon completion of this activity, the registered nurse will have enhanced knowledge regarding breast cancer and be able to describe at least one concept related to breast cancer risk factors, the latest practices and treatment advancements related to breast cancer that can be incorporated into practice as evidenced by a self-reported intent to change practice as stated on the post activity evaluation tool.

EDUCATIONAL METHODS

Didactic Lectures, Panel Discussions, and Question and Answer Sessions

ACCREDITATION AND CREDIT DESIGNATION STATEMENTS

Physicians

Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Houston Methodist designates this live activity for a maximum of 3.75 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing

Houston Methodist is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Houston Methodist will award 3.83 Nursing Continuing Professional Development contact hours for this activity. Participants must attend the activity in its entirety and complete the continuing education evaluation.



Breast Cancer Updates for Primary Care Saturday, January 28, 2023 Houston Methodist Research Institute

HOW TO RECEIVE YOUR CERTIFICATE

Physicians

An email will be sent from learn@houstonmethodist.org with the necessary link to evaluate the activity. You will be prompted to print/download your certificate in PDF format once you have submitted your evaluation.

Nurses

To be awarded up to 3.83 contact hours for this continuing education activity, the participant must:

- o Be sure to check in and complete the sign in process
- o Attend each session in its entirety (Contact hours are awarded only for full day attendance)
- o Complete the evaluation tool. An email will be sent from learn@houstonmethodist.org with the necessary link to evaluate the activity. You will be prompted to print/download your certificate in PDF format once you have submitted your evaluation.

DISCLAIMER AND DISCLOSURES

Houston Methodist makes every effort to develop continuing education activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education and American Nurse Credentialing Center (ANCC), Houston Methodist has implemented a mechanism requiring everyone in a position to control content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers, etc.) to disclose all financial relationships with ineligible companies (companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) and mitigate any relevant financial relationships prior to the activity. Individuals must disclose to participants the existence of financial relationships at the time of the activity and 24 months prior.

Houston Methodist does not view the existence of interests or relationships with ineligible companies as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

In addition, if contributors will be discussing products (drugs/devices) they have been instructed to use generic names and to include various products within and across classes. If at any time during this activity you feel that there has been commercial or promotional bias, please notify the CE coordinator for the activity and note your comments by using the commercial bias comments box in the evaluation form. Please answer the question about balance in the CE activity evaluation candidly.

Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with applicable law.

Faculty members are also asked to disclose any unlabeled use or investigational use (not yet approved for any purpose) or pharmaceutical and medical device products and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.

All in control of content for this activity have no relevant financial relationships with ineligible companies to disclose.

Breast Cancer Updates for Primary Care Saturday, January 28, 2023 Houston Methodist Research Institute

EXHIBITORS

We gratefully acknowledge the following companies for participating as exhibitors at this activity:

Biotheranostics, Inc. – A Hologic Company

Maxim at Home

Merck